表4：舒格利单抗联合化疗对比安慰剂联合化疗一线治疗中国转移性非小细胞肺癌的成本效果分析

数据集获取（Figshare）

• 源站标题：Table_4_Cost-effectiveness analysis of sugemalimab vs. placebo, in combination with chemotherapy, for treatment of first-line metastatic NSCLC in China.DOCX
• DOI：10.3389/fpubh.2022.1015702.s005
• 发布日期：2022-11-03
• 文件数：1 个
• 文件总体积：14.27 KB
• 源站页面：https://frontiersin.figshare.com/articles/dataset/Table_4_Cost-effectiveness_analysis_of_sugemalimab_vs_placebo_in_combination_with_chemotherapy_for_treatment_of_first-line_metastatic_NSCLC_in_China_DOCX/21485520

命令行下载

curl -L -o "Table_4_Cost-effectiveness analysis of sugemalimab vs. placebo, in combination with chemotherapy, for treatment of first-line metastatic NSCLC in Chin.DOCX" "https://ndownloader.figshare.com/files/38085510"

文件清单

• Table_4_Cost-effectiveness analysis of sugemalimab vs. placebo, in combination with chemotherapy, for treatment of first-line metastatic NSCLC in Chin.DOCX（14.27 KB）

文件总体积 14.27 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

ObjectiveThe purpose of this study was to estimate the cost-effectiveness of sugemalimab plus chemotherapy (SC) vs. placebo plus chemotherapy (PC), as the first-line treatment for patients with non-small cell lung cancer (NSCLC) in China.
Material and methodsA three-state Markov model with a cycle of 3 weeks was built to assess the incremental cost-effectiveness ratio (ICER) of SC vs. PC as first-line treatment for patients with NSCLC over a 10-year horizon from Chinese health care perspective. Time-dependency transition probability and safety data were derived from a multicenter, randomized, double-blind, phase 3 clinical trial performed in China (GEMSTONE-302). Primary model outcomes included the costs in US dollars and health outcomes in quality-adjusted life-years (QALYs) and the ICER under a willingness-to-pay (WTP) threshold of $37,663/QALYs. Deterministic, scenario and probabilistic sensitivity analysis were employed to investigate the robustness of model outcomes.
ResultsIn base-case analysis, compared with PC, first-line SC for intention-to-treat (ITT) population gained an additional 0.57 QALYs with an incremental cost of $62,404.15, resulting in an ICER of $109,480.97/QALYs gained. When a patient assistance program (PAP) was available, the ICER decreased to $52,327.02/QALYs. In subgroup analysis, the ICER values were above the WTP threshold with or without PAP. Sensitivity analysis results suggested that the model outcomes were reliable.
ConclusionFrom the perspective of Chinese healthcare system, the SC was not cost-effective in comparison to PC as first-line treatment for NSCLC, regardless of PD-L1 tumor expression level and pathological subtype.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.3389/fpubh.2022.1015702.s005（source: https://frontiersin.figshare.com/articles/dataset/Table_4_Cost-effectiveness_analysis_of_sugemalimab_vs_placebo_in_combination_with_chemotherapy_for_treatment_of_first-line_metastatic_NSCLC_in_China_DOCX/21485520）。